Western Drugmakers Suspected in Russian Procurement Corruption Scandal

Western Drugmakers Suspected in Russian Public Procurement Corruption Scandal

Western pharmaceutical giants including Swiss, British, American, French, and Japanese firms are facing scrutiny over allegations that they built hundreds of millions of dollars in kickbacks into Russian public health procurement contracts, according to an investigation published by the investigative outlet Proekt and detailed by Courrier international.

The calculations stem from sales figures showing that eight major international drug manufacturers sold 386 billion rubles—equivalent to 4.2 billion euros—to the Russian public sector. A pharmaceutical executive identified under the pseudonym Antonina, who oversaw distribution, reported that 10% to 20% of high-cost public drug contracts were funneled into bribes for chief medical officers, security officials, and government bureaucrats. Applying the lowest estimate yields roughly 38.5 billion rubles, or 420 million euros, potentially lost to illicit payments.

Commercial Bonuses and Anticancer Treatments Drive the Scale

The alleged corruption relies heavily on commercial bonuses and kickback structures embedded directly within supply chains. According to Antonina, Russian distributors handling Western imports received commercial bonuses averaging 30% of a drug’s list price, which could swell as high as 60%. These margins financed what industry insiders term procurement support—effectively paying off decision-makers who dictate state drug purchases, pricing, and timing while protecting networks within the power structure.

Cancer treatments sit at the center of the mechanism, accounting for over 40% of public drug spending in Russia. Foreign manufacturers rank among the top ten suppliers to the state health sector, with Swiss firm Roche leading the group and French manufacturer Sanofi placing fourth. Antonina noted that Western laboratories factored these payments into sales forecasts from the outset, while local intermediaries handled the physical disbursement of funds.

Political Connections and the Catalyst for Revelation

While ordinary patients diagnosed with cancer bear the direct human cost of inflated prices—which Proekt estimates could drop by 15% to 25% absent these fees—the primary beneficiaries remain a close circle of business figures and political associates. Proekt identified Russian businessmen Alexei Repik and Viktor Kharitonine as chief suspected beneficiaries. The investigation also notes potential connections between pharmaceutical interests and two daughters of Vladimir Putin, alongside the entourage of Chechen leader Ramzan Kadyrov, though reporters emphasized these links do not independently prove direct involvement in bribery.

Antonina observed these purchasing dynamics for years before deciding to come forward. The death of Russian opposition figure Alexei Navalny on Feb. 16, 2024, served as the turning point that prompted her to share documents and insider testimony. Fin 2025, elle a transmis ses informations à Proekt, servant de point de départ à une enquête sur les achats publics de médicaments en Russie.